bullish
Classys (214150 KS): Will Continue To Remain On a Consistent Growth Path Through New Launches
364 Views11 Jan 2023 19:35
SUMMARY
- Classys (214150 KS) has started selling Volnewmer from the end of October 2022. With a safe and comfortable treatment experience, Volnewmer will become another strong growth engine.
- The ratio of consumables sales to total sales is gradually increasing from 33% in Q1 2022 and 37% in Q2 2022 to 46% in Q3 2022, leading to improved profitability.
- Classys recorded 30%+ revenue growth and margin improvement in Q3, with the cumulative sales in Q3 of this year exceeded 2021 annual sales, which was already the largest.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Jeisys Medical (287410 KS): Solid Q1 Result; New Product Launch and China Expansion to Drive Growth29 May 2023
- InMode Ltd (INMD US): Decelerating Growth & Unfavorable Macro Environment Are Major Concerns26 Feb 2023
- Classys (214150 KS): Record-High Sales and Profit in 2022; Geography Expansion to Accelerate Growth17 Feb 2023
- Classys (214150 KS): Will Continue To Remain On a Consistent Growth Path Through New Launches11 Jan 2023
- Classys (214150 KS): Overseas Expansion +Portfolio Enlargement = Consistent & Sustainable Growth25 Sep 2022
- Classys (214150 KS): Bain Capital Deal Implies 11% Upside Potential30 Jan 2022
x